Carl Dambkowski is Chief Medical Officer at Apogee Therapeutics, Inc. (APGE). They have made 3 open-market trades across 1 company since 2024, most recently 2026-07-14.
CIK 0001983476
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APGE | 169,873 | $22.9M |
| ORKA | 38,743 | $2.8M |
| Total | $25.7M |
Shares reported on the most recent Form 4, priced at the 2026-07-16 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APGE | SELL · 10b5-1 | 2026-07-01 | 2026-07-02 | $132.74 | $730K | +0.8% | +0.7% | N/A |
| APGE | SELL · 10b5-1 | 2026-06-22 | 2026-06-24 | $132.60 | $3.5M | +0.5% | +1.1% | N/A |
| ORKA | SELL · 10b5-1 | 2026-06-11 | 2026-06-12 | $70.13 | $2.5M | +22.7% | +19.1% | +29.3% |
| APGE | SELL · 10b5-1 | 2026-06-03 | 2026-06-05 | $78.71 | $433K | +0.6% | +51.9% | N/A |
| ORKA | SELL · 10b5-1 | 2026-05-21 | 2026-05-22 | $58.97 | $6.2M | +1.9% | +39.8% | +71.5% |
| APGE | SELL · 10b5-1 | 2026-05-06 | 2026-05-08 | $84.14 | $463K | -5.2% | -3.4% | +56.5% |
| APGE | SELL · 10b5-1 | 2026-04-01 | 2026-04-03 | $84.84 | $467K | +6.2% | -0.7% | +58.0% |
| APGE | SELL | 2026-03-04 | 2026-03-06 | $71.06 | $391K | -8.6% | +15.0% | +24.3% |
| APGE | SELL | 2026-02-04 | 2026-02-04 | $65.79 | $362K | +7.5% | +12.8% | +28.4% |
| APGE | SELL | 2026-01-07 | 2026-01-09 | $77.84 | $1.5M | +2.5% | -20.2% | +11.1% |
| APGE | SELL · 10b5-1 | 2025-12-04 | 2025-12-05 | $75.00 | $818K | -0.7% | +2.0% | -6.7% |
| APGE | SELL · 10b5-1 | 2025-11-05 | 2025-11-07 | $55.24 | $906K | +13.6% | +35.4% | +10.6% |
| APGE | SELL · 10b5-1 | 2025-10-01 | 2025-10-03 | $39.80 | $203K | +40.2% | +36.4% | +90.2% |
| APGE | SELL · 10b5-1 | 2025-09-03 | 2025-09-05 | $37.85 | $199K | -0.9% | +4.8% | +98.7% |
| APGE | SELL · 10b5-1 | 2025-08-06 | 2025-08-08 | $37.78 | $206K | +1.8% | +8.6% | +55.4% |
| APGE | SELL · 10b5-1 | 2025-07-02 | 2025-07-03 | $45.04 | $875K | -18.8% | -21.2% | -16.7% |
| APGE | SELL · 10b5-1 | 2025-06-04 | 2025-06-06 | $36.96 | $101K | -0.7% | -5.4% | -10.5% |
| APGE | SELL · 10b5-1 | 2025-05-07 | 2025-05-09 | $35.75 | $195K | +1.7% | +1.6% | -8.8% |
| APGE | SELL · 10b5-1 | 2025-04-02 | 2025-04-04 | $35.96 | $228K | -1.4% | +21.2% | +46.1% |
| APGE | SELL · 10b5-1 | 2025-03-05 | 2025-03-07 | $30.48 | $48K | +13.9% | -9.0% | +6.0% |
| APGE | SELL · 10b5-1 | 2025-02-05 | 2025-02-07 | $40.69 | $286K | -14.8% | -5.8% | -5.1% |
| APGE | SELL · 10b5-1 | 2025-01-02 | 2025-01-03 | $46.93 | $379K | -22.9% | -15.2% | -26.5% |
| APGE | SELL · 10b5-1 | 2024-12-11 | 2024-12-13 | $48.69 | $420K | +2.9% | -10.8% | -16.4% |
| APGE | SELL · 10b5-1 | 2024-12-04 | 2024-12-06 | $46.07 | $614K | -10.3% | -3.1% | -28.9% |
| APGE | SELL · 10b5-1 | 2024-11-06 | 2024-11-08 | $59.12 | $788K | -29.1% | -22.7% | -34.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.